An observational study in Acute Lymphoblastic Leukemia, Pediatric, sponsored by Xiaojun Xu. Status unknown. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2023-05-01.
Sponsored by Xiaojun Xu · Observational
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.
2,061 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 490 are open to participants now.
This study's planned enrollment of 20 is below the median of 120 across 300 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →This is the only study on the registry with Xiaojun Xu as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Pediatric BCP-ALL patients who were treated in our institution since Oct 2021
Exclusion Criteria:
IV
MRD clearance rate (MRD<0.00001%)
The change of MRD will be detected by NGS, with sensitivity of 0.00001% and 0.01%, respectively
Time frame: before blinatumomab initiation (baseline), Day 15 of blinatumomab treatment, Day 29 of blinatumomab treatment
No study locations are listed for this record.
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma→